Barsony J, Renyi I, McKoy W, Kang H C, Haugland R P, Smith C L
Metabolic Diseases Branch, National Institute of Diabetes, Digestive, and Kidney Diseases, National Cancer Institute, Bethesda, Maryland 20892-0850, USA.
Anal Biochem. 1995 Jul 20;229(1):68-79. doi: 10.1006/abio.1995.1380.
To gain better insight into the mechanism of steroid receptor activation and calcitriol action, we have developed the first pharmacologically relevant fluorescent-labeled ligand for the vitamin D receptor (VDR). Purity and structure of three BODIPY-labeled calcitriol derivatives were characterized by TLC, HPLC, and 1H-NMR spectroscopy. 3 beta-BODIPY-calcitriol was the most potent derivative to induce 25-hydroxyvitamin D3 24-hydroxylase activity and to inhibit cell proliferation. It was taken up rapidly and specifically and was not cleaved by endogenous esterases. 3 beta-BODIPY-calcitriol also retained high-affinity binding to the VDR. Hormone binding to the receptor was measured by spectrofluorometry in high-salt extracts from cultured cells with wild-type VDR, from cells virally over-expressing the human VDR, and in intact cells with and without VDR. Results from fluorescent binding studies agreed with results from radioligand assays. The most useful feature of this reagent is that its fluorescence emission increases severalfold upon binding to VDR. This allows direct monitoring by microscopy of ligand receptor interactions in living cells. Fluorescent-labeled calcitriol can be a valuable diagnostic tool for cancer research and is essential for exploring the subcellular localization of VDRs.
为了更深入地了解类固醇受体激活和骨化三醇作用的机制,我们开发了第一种与维生素D受体(VDR)具有药理学相关性的荧光标记配体。通过薄层色谱法(TLC)、高效液相色谱法(HPLC)和1H-核磁共振光谱法对三种硼二吡咯(BODIPY)标记的骨化三醇衍生物的纯度和结构进行了表征。3β-BODIPY-骨化三醇是诱导25-羟基维生素D3 24-羟化酶活性和抑制细胞增殖的最有效衍生物。它能迅速且特异性地被摄取,并且不会被内源性酯酶裂解。3β-BODIPY-骨化三醇还保留了与VDR的高亲和力结合。通过荧光分光光度法在来自具有野生型VDR的培养细胞的高盐提取物中、来自病毒过表达人VDR的细胞中以及在有和没有VDR的完整细胞中测量激素与受体的结合。荧光结合研究的结果与放射性配体测定的结果一致。该试剂最有用的特点是其荧光发射在与VDR结合后会增加几倍。这使得可以通过显微镜直接监测活细胞中配体与受体的相互作用。荧光标记的骨化三醇可以成为癌症研究中有价值的诊断工具,并且对于探索VDR的亚细胞定位至关重要。